UK corporate updates highlighted momentum across financial services and healthcare, even as consumer-facing businesses faced persistent macroeconomic headwinds. Wise Group and Aviva both delivered robust operational growth, with Wise posting a 23% surge in half-year net revenue to $1.45bn on strong cross-border transaction volumes, while Land Securities maintained stable earnings supported by a 6.2% like-for-like income rise. In contrast, DFS Furniture reported a 2.5% drop in early FY27 order intake as squeezed household budgets dampened retail demand. Meanwhile, healthcare and biotech firms secured significant regulatory milestones, marked by positive European opinions for GSK’s Bexsero booster and Agronomics-backed Solar Foods, alongside full US EPA approval for Eden BioSolutions' biofungicide.
Insurance giant Aviva AV. issued its Q3 2026 trading update, demonstrating sustained growth across core markets in the UK, Ireland, and Canada. The group reaffirmed its financial targets, staying on course to deliver £2.0bn in operating profit by 2026 alongside strong capital generation. Management highlighted continued net inflows in wealth management and robust premium growth in general insurance, maintaining the positive outlook established at its full-year results.
Upholstered furniture retailer DFS Furniture DFS warned of challenging market conditions ahead of its AGM, noting that demand has softened further over the past seven weeks. Following a 2.5% year-on-year order intake decline in the first 12 weeks of FY27, persistent pressure on household budgets has weighed on consumer footfall across the sector. Proprietary banking data indicates core retail brands DFS and Sofology continue to gain market share, prompting management to step up commercial initiatives ahead of Black Friday and winter sales.
Financial technology firm Wise Group WISE posted strong half-year results for FY27, driven by expanding international customer adoption. Net revenue grew 23% year-on-year to $1.45bn as total cross-border transfer volume reached $141.0bn, up 24% from the prior period. Active customers increased 21% to 16.2 million, while customer holdings rose 28% to $43.5bn, benefiting from expanding bank partnerships and direct clearing connections.
Commercial property developer Land Securities Group LAND delivered resilient half-year results, reporting stable EPRA earnings of £192m despite portfolio asset sales. Like-for-like net rental income grew 6.2%, while administrative overheads were cut by 9%, helping offset lost income from previous disposals. Chief Executive Mark Allan confirmed that strong customer demand for prime real estate reinforces the group's target of delivering a 5% compound annual growth rate in EPRA earnings per share through FY30.
Pharmaceuticals group GSK GSK announced that the EMA's Committee for Medicinal Products for Human Use has recommended approval for a single booster dose of its Meningitis B vaccine, Bexsero. The recommendation applies to individuals aged 10 years and older who received primary vaccination at least two years prior. Clinical trial data confirmed that immune memory established in infancy can be reinforced up to 19 years later, offering sustained protection during adolescent peaks of invasive meningococcal disease.
Commercial biotechnology business Allergy Therapeutics AGY announced a 9% increase in full-year revenue to £59.9m for the year ended 30 June 2026. Growth picked up to more than 12% in the second half following the German roll-out of its Grassmuno immunotherapy treatment. Financial stability was substantially enhanced during the year, with shareholder debt fully paid off and replaced by a new £40m facility from Hayfin, leaving cash reserves at £24.2m.
Cellular agriculture investor Agronomics ANIC announced a major regulatory step for portfolio company Solar Foods, which received a positive safety opinion from the European Food Safety Authority. Solein, a novel food protein produced from carbon dioxide and electricity using gas fermentation, passed EFSA safety evaluations. The application now progresses to the European Commission for final commercial approval, expected within seven to nine months.
Sustainable biopesticide developer Eden BioSolutions EDEN has achieved unconditional regulatory registration from the US Environmental Protection Agency for its Mevalone Delta product. The approval covers a wide selection of high-value agricultural crops with a total US farm-gate value of approximately $33bn. Utilizing the company's proprietary microencapsulation technology, the biofungicide can now be commercialized across key North American farming regions.